Your browser doesn't support javascript.
loading
Follow-up of Cystic Pineal Glands in Retinoblastoma Patients Does Not Increase Detection of Pineal Trilateral Retinoblastoma.
de Bloeme, Christiaan M; Jansen, Robin W; de Haan, Joeka; Pieperjohanns, Debbie; Casseri, Tommaso; Gironi, Federica; Pasca, Alessandra; Ketteler, Petra; Moll, Annette C; Koob, Meriam; Sirin, Selma; Maeder, Philippe; Galluzzi, Paolo; Göricke, Sophia; de Graaf, Pim; de Jong, Marcus C.
Afiliación
  • de Bloeme CM; From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Cancer Center Amsterdam, Imaging and Biomarkers (C.M.d.B., R.W.J., J.d.H., A.C.M., P.d.G., M.C.d.J.), Amsterdam, the Netherlands; Department of Radiology and Nuclear Medi
  • Jansen RW; From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Cancer Center Amsterdam, Imaging and Biomarkers (C.M.d.B., R.W.J., J.d.H., A.C.M., P.d.G., M.C.d.J.), Amsterdam, the Netherlands; Department of Radiology and Nuclear Medi
  • de Haan J; Cancer Center Amsterdam, Imaging and Biomarkers (C.M.d.B., R.W.J., J.d.H., A.C.M., P.d.G., M.C.d.J.), Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam (C.M.d.B., R.W.J., J.d.H., P.d.G., M.C.d.J.), Amsterdam, the Netherlands
  • Pieperjohanns D; Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen (D.P., S.G.), Essen, Germany.
  • Casseri T; Department of Neuroimaging and Neurointervention, Siena University Hospital (T.C., P.G.), Siena, Italy.
  • Gironi F; Department of Neuroimaging and Neurointervention, Siena University Hospital (T.C., P.G.), Siena, Italy; Department of Pediatrics and Neonatology, Siena University Hospital (F.G., A.P.), Siena, Italy.
  • Pasca A; Department of Pediatrics and Neonatology, Siena University Hospital (F.G., A.P.), Siena, Italy.
  • Ketteler P; Department of Pediatric Oncology, University Hospital Essen (P.K.), Essen, Germany.
  • Moll AC; Cancer Center Amsterdam, Imaging and Biomarkers (C.M.d.B., R.W.J., J.d.H., A.C.M., P.d.G., M.C.d.J.), Amsterdam, the Netherlands; Department of Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam (A.C.M.), Amsterdam, the Netherlands.
  • Koob M; From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (M.K., P.M.), Lausanne, Switzerland.
  • Sirin S; From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Department of Diagnostic Imaging, University Children's Hospital Zurich, University of Zurich (S.S.), Zurich, Switzerland.
  • Maeder P; From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (M.K., P.M.), Lausanne, Switzerland.
  • Galluzzi P; From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Department of Neuroimaging and Neurointervention, Siena University Hospital (T.C., P.G.), Siena, Italy.
  • Göricke S; From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen (D.P., S.G.), Essen, Germany.
  • de Graaf P; From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Cancer Center Amsterdam, Imaging and Biomarkers (C.M.d.B., R.W.J., J.d.H., A.C.M., P.d.G., M.C.d.J.), Amsterdam, the Netherlands; Department of Radiology and Nuclear Medi
  • de Jong MC; From the European Retinoblastoma Imaging Collaboration (ERIC) (C.M.d.B., R.W.J., M.K., S.S., P.M., P.G., S.G., P.d.G., M.C.d.J.); Cancer Center Amsterdam, Imaging and Biomarkers (C.M.d.B., R.W.J., J.d.H., A.C.M., P.d.G., M.C.d.J.), Amsterdam, the Netherlands; Department of Radiology and Nuclear Medi
Am J Ophthalmol ; 268: 199-211, 2024 Jul 09.
Article en En | MEDLINE | ID: mdl-38992673
ABSTRACT

PURPOSE:

To evaluate the effectiveness of baseline screening and follow-up with magnetic resonance imaging (MRI) for detecting trilateral retinoblastoma (TRb) and assessing the risk of TRb development.

DESIGN:

Prospective multicenter cohort study.

METHODS:

A total of 607 retinoblastoma patients from 2012 through 2022 were included and followed up until September 1, 2023. At each center, a neuroradiologist categorized pineal glands on baseline and follow-up scans into 4 groups (A) normal, (B) cystic gland, (C) suspicious gland, or (D) TRb. Different follow-up schedules were assigned to each category. Categories B and C were followed up with MRI after approximately 3 months and repeated 3 months later if suspicion remained. On each MRI, they measured the height and width, evaluated the aspect (solid, partly cystic, and completely cystic) of the pineal gland, and evaluated radiologic features suspicious of pineal TRb. The effectiveness of the current TRb screening method was assessed by evaluating its sensitivity and specificity to detect TRb. Determining the TRb incidence was a secondary outcome measure.

RESULTS:

Heritable retinoblastoma patients had a risk of 3.78% to develop TRb. One of 4 pineal TRbs was detected during a follow-up scan and 4 of 5 nonpineal TRbs were detected on the baseline MRI. Screening for pineal TRb had a sensitivity of 25% and specificity of 100%; for nonpineal TRb, the sensitivity was 80%. It required 494 follow-up scans to detect 1 pineal TRb. However, when restricting the follow-up to solely suspicious glands, only 22 scans were required to detect 1 pineal TRb.

CONCLUSION:

During extended follow-up after baseline MRI, only 1 pineal trilateral retinoblastoma was detected in our study. Follow-up after 3 months should be restricted to patients with a suspicious pineal gland defined as irregular thickening of the cyst wall (>2 mm), fine nodular aspect of the cyst wall, or when a solid or cystic gland exceeds the upper 99% prediction interval for size; patients with an unsuspicious cystic gland should not be followed up. Baseline MRI screening was able to detect most nonpineal trilateral retinoblastomas.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Ophthalmol Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Ophthalmol Año: 2024 Tipo del documento: Article
...